Gilead Cuts Deal With MicroDose

Xconomy San Francisco — 

Gilead Sciences (NASDAQ: GILD) said today it has obtained a license from MicroDose Therapeutx to an inhalable small molecule drug for respiratory syncytial virus (RSV). Foster City-based Gilead agreed to make an upfront cash payment, research funding, milestone payments, and royalties on product sales to Monmouth Junction, NJ-based MicroDose. The dollar amount of the deal wasn’t disclosed. RSV infections are estimated to cause 125,000 infants to be hospitalized each year.